James Paton And Suzi Ring Bloomberg
-
{
- All
- News
-
Rise Of Variants Sparks Push For All-In-One Coronavirus Vaccines
Just weeks into the rollout of vaccines to combat Covid-19, researchers are shifting their focus to a new class of potential shots to take on the threat posed by fast-spreading mutations.
-
Oxford Vaccine Effective But Questions On Those Above 55: Report
On the day Britain began immunizing its population with a Covid-19 shot developed by Germany's BioNTech SE and the U.S.'s Pfizer Inc., a peer-reviewed study of the U.K.'s homegrown vaccine left some key questions unanswered.
-
Oxford Vaccine's Counter To Mounting Criticism: A New Global Trial
AstraZeneca Plc's Covid-19 vaccine looks like it's headed for an additional global trial as the drugmaker tries to clear up uncertainty and confusion surrounding favorable results in its current study.
-
Oxford Vaccine Faces More Questions After AstraZeneca Admits Error
AstraZeneca Plc and the University of Oxford, among the front-runners in the quest to deliver a Covid-19 vaccine, face mounting questions about their trial results after acknowledging a manufacturing error.
-
Pfizer, Moderna Boost Hopes But Many Nations Counting On Oxford Vaccine
Trial successes from Pfizer Inc. and Moderna Inc. have buoyed hopes that a Covid-19 vaccine is coming soon. But much of the world, outside of rich nations like the U.S., is counting on another company's shot to escape the crisis.
-
UK Considers Infecting People With Covid To Aid Vaccine Efforts
Alex Greer says he'd rather put himself directly in the path of the coronavirus than get blindsided by the disease after an evening at the pub or with friends. It's a scenario that could soon become a reality.
-
Rise Of Variants Sparks Push For All-In-One Coronavirus Vaccines
Just weeks into the rollout of vaccines to combat Covid-19, researchers are shifting their focus to a new class of potential shots to take on the threat posed by fast-spreading mutations.
-
Oxford Vaccine Effective But Questions On Those Above 55: Report
On the day Britain began immunizing its population with a Covid-19 shot developed by Germany's BioNTech SE and the U.S.'s Pfizer Inc., a peer-reviewed study of the U.K.'s homegrown vaccine left some key questions unanswered.
-
Oxford Vaccine's Counter To Mounting Criticism: A New Global Trial
AstraZeneca Plc's Covid-19 vaccine looks like it's headed for an additional global trial as the drugmaker tries to clear up uncertainty and confusion surrounding favorable results in its current study.
-
Oxford Vaccine Faces More Questions After AstraZeneca Admits Error
AstraZeneca Plc and the University of Oxford, among the front-runners in the quest to deliver a Covid-19 vaccine, face mounting questions about their trial results after acknowledging a manufacturing error.
-
Pfizer, Moderna Boost Hopes But Many Nations Counting On Oxford Vaccine
Trial successes from Pfizer Inc. and Moderna Inc. have buoyed hopes that a Covid-19 vaccine is coming soon. But much of the world, outside of rich nations like the U.S., is counting on another company's shot to escape the crisis.
-
UK Considers Infecting People With Covid To Aid Vaccine Efforts
Alex Greer says he'd rather put himself directly in the path of the coronavirus than get blindsided by the disease after an evening at the pub or with friends. It's a scenario that could soon become a reality.
